Physician profile
Stephen A Besh
NPI 1659375392
$914.57
in general payments reported to CMS, 2019-2025
23 companies · $720 in 2025
The $720 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2023: $183 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.67 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $164.98 | 2023 | |
| Pfizer INC. | $87.67 | 2025 | |
| Novartis Pharmaceuticals Corporation | $86.57 | 2025 | |
| Adaptive Biotechnologies Corporation | $62.21 | 2025 | Clonoseq |
| Gilead Sciences, INC. | $60.38 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $42.07 | 2025 | Enhertu |
| Merck Sharp & Dohme LLC | $41.45 | 2025 | Keytruda, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $39.01 | 2025 | Opdualag |
| Puma Biotechnology, INC. | $35.55 | 2025 | |
| Servier Pharmaceuticals LLC | $30.30 | 2025 | |
| Caris Mpi, INC. | $28.06 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $27.69 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $27.27 | 2025 | Enhertu |
| Celgene Corporation | $26.18 | 2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $26.02 | 2025 | Ninlaro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $25.81 | 2025 | Verzenio, Jaypirca |
| Eisai INC. | $20.76 | 2025 | |
| Stemline Therapeutics INC. | $18.16 | 2025 | Orserdu |
| G1 Therapeutics, INC. | $17.91 | 2023 | Cosela |
| Taiho Oncology, INC. | $16.34 | 2025 | |
| Sobi, INC | $15.86 | 2025 | |
| Array Biopharma INC | $14.32 | 2025 | Lorbrena, Mektovi, Braftovi |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Besh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.